Patient Cures Spur Demand for $1,000 Hepatitis C Pill

July 24, 2014 5:48 AM

6 0

The powerful new hepatitis C drug that sent Gilead Sciences Inc. (GILD:US)’s sales soaring last quarter is doing the same for the hopes of millions of patients.

Sandra Cabrera and Ted Tabor both suffered devastating damage from hepatitis C. After just weeks of taking Gilead’s Sovaldi, they feel much better and tests suggest the lethal virus is disappearing from their blood.

Read more

To category page